Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
C. M. Nijenhuis, J. H. M. Schellens & J. H. Beijnen. (2016) Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metabolism Reviews 48:2, pages 266-280.
Read now
Read now
Mark M Awad & Ryan J Sullivan. (2015) Dabrafenib in combination with trametinib for the treatment of metastatic melanoma. Expert Review of Clinical Pharmacology 8:1, pages 25-33.
Read now
Read now
Articles from other publishers (17)
Jakub Witkowski, Sebastian Polak, Dariusz Pawelec & Zbigniew Rogulski. (2023) In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III. International Journal of Molecular Sciences 24:3, pages 2239.
Crossref
Crossref
Eugene Y. Tan, Marketa Pazdirkova, Amanda J. Taylor, Namrata Singh & Ganesh R. Iyer. (2023) Evaluation of a Low‐Fat Low‐Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open‐Label, 2‐Part Study in Healthy Participants. Clinical Pharmacology in Drug Development.
Crossref
Crossref
Simon G. Wong & Shuguang Ma. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development
137
174
.
Eugene Y. Tan, Ovidiu Chiparus, Somesh Choudhury, Christina Kim, Mike Lau, Christoph Ziltener & Palanichamy Ilankumaran. (2022) Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long‐Term Storage at Room Temperature. Clinical Pharmacology in Drug Development 11:10, pages 1203-1210.
Crossref
Crossref
Hendrik‐Tobias Arkenau, Donatienne Taylor, Xiaoying Xu, Shripad Chitnis, Casilda Llacer‐Perez, Kathleen Moore, Prasanna Kumar Nidamarthy, Palanichamy Ilankumaran & Judith De Vos‐Geelen. (2022) Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors. Clinical Pharmacology in Drug Development 11:5, pages 585-596.
Crossref
Crossref
W.M.A. Niessen, H. Rosing & J.H. Beijnen. (2021) Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites. International Journal of Mass Spectrometry 464, pages 116559.
Crossref
Crossref
W.M.A. Niessen, M.J.X. Hillebrand, H. Rosing & J.H. Beijnen. (2021) Tandem mass spectrometry of small-molecule signal transduction inhibitors: Accurate-m/z data to adapt structure proposals of product ions. Journal of Pharmaceutical and Biomedical Analysis 195, pages 113864.
Crossref
Crossref
Jingcheng Xiao, Doanh Tran, Xinyuan Zhang, Tao Zhang, Shirley Seo, Haojie Zhu & Peng Zou. (2020) Biliary Excretion–Mediated Food Effects and Prediction. The AAPS Journal 22:6.
Crossref
Crossref
Hannah Yejin Kim, Parth J. Upadhyay, Alia Fahmy, Xiaoman Liu, Janna K. Duong & Alan V. Boddy. (2019) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. Clinical Pharmacokinetics 58:8, pages 1029-1043.
Crossref
Crossref
Pramod C. Nair, Ross A. McKinnon & John O. Miners. (2019) Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. Drug Metabolism and Disposition 47:6, pages 616-631.
Crossref
Crossref
Hannah Yejin Kim, Janna K. Duong, Maria Gonzalez, Georgina V. Long, Alexander M. Menzies, Helen Rizos, Su Yin Lim, Jenny Lee & Alan V. Boddy. (2019) Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology 83:4, pages 693-704.
Crossref
Crossref
Yaakov Cass, Thomas H Connor & Alexander Tabachnik. (2016) Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting. Journal of Oncology Pharmacy Practice 23:5, pages 350-378.
Crossref
Crossref
Oliver von Richter, Giorgio Massimini, Holger Scheible, Istvan Udvaros & Andreas Johne. (2016) Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. British Journal of Clinical Pharmacology 82:6, pages 1498-1508.
Crossref
Crossref
Sohita Dhillon. (2016) Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation. Targeted Oncology 11:3, pages 417-428.
Crossref
Crossref
Claire Beaumont, Graeme C. Young, Tom Cavalier & Malcolm A. Young. (2014) Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. British Journal of Clinical Pharmacology 78:6, pages 1185-1200.
Crossref
Crossref
Lufang Zhou, Ningning Xu, Yan Sun & Xiaoguang (Margaret) Liu. (2014) Targeted biopharmaceuticals for cancer treatment. Cancer Letters 352:2, pages 145-151.
Crossref
Crossref
Cathrine Leonowens, Carolyn Pendry, John Bauman, Graeme C. Young, May Ho, Frank Henriquez, Lei Fang, Royce A. Morrison, Keith Orford & Daniele Ouellet. (2014) Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. British Journal of Clinical Pharmacology 78:3, pages 524-532.
Crossref
Crossref